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Objectives: Posthoc analysis of treatment satisfaction in patients switching to subcutaneous
(SC) peginterferon beta-1a in the ALLOW study.
Patients and methods: Patients with relapsing multiple sclerosis treated with intramuscular
interferon (IFN) beta-1a or SC IFN beta-1a or beta-1b remained on their current therapy for
a 4-week run-in period, followed by a switch to SC peginterferon beta-1a 125 mcg every 2
weeks for 48 weeks. Treatment satisfaction was measured using the Treatment Satisfaction
Questionnaire for Medication (TSQM), which covers effectiveness, side effects, convenience,
and global satisfaction. Patients completed the TSQM at baseline (prior to starting the 4-week
run-in period) and 4, 12, 24, 36, and 48 weeks after switching, and scores were analyzed for the
overall population and compared to baseline. Patients reported the severity of flu-like symptoms
(FLS) at baseline and with each peginterferon beta-1a injection; clinicians evaluated the occurrence of injection-site reactions (ISRs) after the first dose of peginterferon beta-1a and every
12 weeks thereafter. TSQM scores were stratified by the presence of FLS or ISRs during the
study period and by prior IFN therapy use.
Results: For the overall population (n=194), convenience and global satisfaction scores significantly improved from baseline at all time points, and side effect satisfaction scores significantly
improved up to week 36. Convenience scores significantly improved regardless of FLS, ISRs,
or prior IFN therapy. Patients without FLS during the study period showed significant improvements in global satisfaction, but not side effect satisfaction, versus those with FLS. Patients
switching from SC IFN therapies achieved greater improvements in treatment satisfaction than
patients who switched from intramuscular IFN beta-1a.
Conclusions: Switching relapsing multiple sclerosis patients to SC peginterferon beta-1a from
other IFN therapies significantly improved treatment satisfaction and convenience.
Keywords: interferon beta-1a, interferon beta-1b, peginterferon beta-1a, relapsing multiple
sclerosis, treatment satisfaction, Treatment Satisfaction Questionnaire for Medication, TSQM,
quality of life, patient-reported outcomes
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Interferon (IFN) beta-based disease-modifying therapies (DMTs) are well-established
treatments approved for relapsing forms of multiple sclerosis (RMS). Intramuscular
(IM) IFN beta-1a, subcutaneous (SC) IFN beta-1a, and SC IFN beta-1b have wellcharacterized efficacy and safety profiles.1,2 SC peginterferon beta-1a is the most recently
approved IFN for the treatment of RMS, is administered every 2 weeks, and has a safety
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and tolerability profile consistent with the IFN class, with the
most common adverse events (AEs) including flu-like symptoms (FLS) and injection-site reactions (ISRs).3–5 However, in
a Phase I crossover study in healthy volunteers, AEs occurred
less frequently with SC peginterferon beta-1a than with SC
IFN beta-1a three times a week over 2 weeks despite 60%
higher levels of drug exposure.3 In addition, the ALLOW
study, a Phase IIIb, open-label, randomized study in patients
with RMS who switched from a nonpegylated IFN to peginterferon beta-1a, found the vast majority of patients (89.6%) did
not show new or worsening FLS after the switch.6,7
While the primary objective of ALLOW was to assess
FLS in patients switching to peginterferon beta-1a,6,7 participating patients also reported their satisfaction with the
therapy. Patient-reported treatment satisfaction is based on
factors such as convenience (eg, route of administration and
dosing frequency), effectiveness, and side effects.8,9 Treatment satisfaction has also been shown to affect treatment
adherence and persistence; nonadherence to DMTs has
been associated with reduced treatment effectiveness (eg,
increased relapse/progression) and may lead to increased
hospitalization rates and MS-related costs.10,11 These findings
highlight the ongoing need to evaluate and improve patients’
treatment satisfaction.12 Monitoring treatment satisfaction
may also help to identify patients who may be at risk of
poor medication adherence,13 highlighting an opportunity to
change medication or implement patient education.
Patient-reported treatment satisfaction has been measured
using a variety of instruments, including the Treatment
Satisfaction Questionnaire for Medication (TSQM), a validated, psychometrically sound measure for the assessment
of patients’ satisfaction with medication.13 The TSQM has
been validated in patients with RMS and has been used to
measure satisfaction with DMTs.12,14
This posthoc analysis was conducted to assess patientreported treatment satisfaction in patients with RMS who
switched from a nonpegylated IFN beta therapy to SC
peginterferon beta-1a as a part of the ALLOW study.

Patients and methods
The ALLOW study design has been described previously.6,7
The study enrolled patients aged 18–65 years with RMS
treated with a stable dose of nonpegylated IFN for $4 months
immediately prior to screening. Patients remained on their
current therapy for a 4-week run-in period followed by a
switch to SC peginterferon beta-1a (125 mcg every 2 weeks)
and were followed for a total of 48 weeks.
The primary end point of the ALLOW study was the proportion of patients experiencing new or worsening FLS during the
1290
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first 8 weeks of SC peginterferon beta-1a therapy.6,7 Secondary
end points included patient-reported treatment satisfaction.
Patients completed the TSQM at baseline (prior to the
run-in period when patients were receiving nonpegylated
IFN) and 4, 12, 24, 36, and 48 weeks after switching to
peginterferon beta-1a. The TSQM comprises 14 items covering four domains: effectiveness, side effects, convenience,
and global satisfaction.13,14 The TSQM items utilize a 5- or
7-point Likert-type scale. A score for each domain is calculated by summing the corresponding items transformed on a
0–100 scale; higher values indicate higher satisfaction.15
TSQM scores at baseline were compared to TSQM scores
at each postswitching visit for the overall efficacy population, defined as patients who received at least one dose of SC
peginterferon beta-1a and had TSQM data during the 4-week
run-in period and during the postswitching treatment period.
All data were analyzed using observed data; no imputation
was performed for missing data. TSQM scores were analyzed
for the impact of ISRs or FLS occurrence at any point during
the study, as well as by prior IFN therapy. FLS were assessed
using the total FLS score (FLS-S). Patients were assigned a
score from 0 to 3 to their muscle aches, chills, and fatigue as
follows: “0” for absent; “1” for mild, did not interfere with
daily activities; “2” for moderate, sufficient to interfere with
daily activities; and “3” for severe, bedrest required. Patients’
body temperatures were also assigned a score from 0 to 3: “0”
if ,99.1°F, “1” if $99.1°F but ,100.1°F, “2” if $100.1°F
but ,101.1°F, and “3” if $101.1°F, allowing a total FLS-S
ranging from 0 to 12. As defined in the protocol for the primary end point for the study, a patient with an FLS-S increase
of $2 from the 4-week run-in period was regarded as having
FLS. The effect of prior IFN therapy on changes in baseline
TSQM scores was compared in patients previously treated
with IM IFN beta-1a or SC IFN beta-1a or beta-1b.
Changes from baseline were recorded using transformed
scores between 0 and 100 and analyzed using a paired t-test
and a significance level of 0.05. Linear regression analysis
was used over all visits. Comparisons between prior IFN
therapies, FLS status, and ISR status were analyzed using
a two-sample t-test and a significance level of 0.05. To justify the use of t-tests, data were also analyzed by Wilcoxon
signed-rank test or Wilcoxon rank-sum tests; P-values from
the two types of tests were similar.
The study was performed in accordance with the Declaration of Helsinki and in compliance with the International
Council for Harmonisation and Good Clinical Practice. The
study protocol and amendments were approved by each study
site’s local ethics committee (Table S1), and all patients
provided written informed consent.
Patient Preference and Adherence 2018:12
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Of the 201 patients randomized into ALLOW, 164 (81.6%)
completed the study. Reasons for not completing the study
were withdrawal due to AEs (13.4%), consent withdrawn
(3.5%), and others (1.5%). The intent-to-treat (ITT) population (the cohort for ALLOW study analysis) comprised 201
randomized patients who received at least one dose of SC
peginterferon beta-1a. Baseline characteristics of the ITT
population are shown in Table S2. The efficacy population
consisted of 194 randomized patients who received at least
one dose of SC peginterferon beta-1a and had efficacy data
at baseline and postswitching, the cohort for the current
analysis. No differences were seen in baseline characteristics
between the ITT and efficacy populations.
Nonpegylated IFN therapies taken prior to switching
across the ITT population (n=201) were IM IFN beta-1a
(50.8%), SC IFN beta-1a (25.4%), SC IFN beta-1b (19.4%),
and unknown (4.5%).

TSQM scores: overall efficacy population
Changes from baseline to each postswitching visit using
transformed scores between 0 and 100 are presented for
the overall efficacy population in Figure 1. The changes
from baseline in convenience and global satisfaction scores
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were statistically significant at all postswitching time points
through week 48 (all P,0.0001; Figure 1). Side effect scores
were also significantly improved compared with baseline
for all visits (P,0.05) except week 48. Trends toward
small improvements in effectiveness scores were seen at
later time points, although the changes were not statistically
significant.

TSQM scores: by FLS status
A quarter (49/194) of patients experienced FLS at any point
in the study. We analyzed TSQM scores in patients who
did versus those who did not experience FLS to determine
whether FLS had any impact on treatment satisfaction.
Regardless of whether patients experienced FLS, significant improvements in mean TSQM side effect scores were
observed from baseline to week 4, returning to near-baseline
levels by week 48 (Figure 2). Significant improvements
in mean TSQM convenience scores from baseline to each
subsequent study visit were seen regardless of FLS (all
P,0.0001).
Patients who did not experience FLS reported significant
improvements from baseline in mean TSQM global satisfaction at all subsequent visits (all P,0.0001). In contrast,
patients who experienced FLS saw an improvement in
mean TSQM global satisfaction only from baseline to
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Patients






±
±



   



   



   



   

:HHNVDIWHUEDVHOLQH
Figure 1 Improvement in overall TSQM scores from baseline.
Notes: *P,0.05, ***P,0.001, and ****P,0.0001 compared with baseline. Data are mean values ±95% CI.
Abbreviation: TSQM, Treatment Satisfaction Questionnaire for Medication.
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Figure 2 Improvement in TSQM scores (with or without FLS).
Notes: *P,0.05, **P,0.01, ***P,0.001, ****P,0.0001 compared with baseline. Data are mean values ±95% CI. A patient was considered to have FLS if FLS-S total score
was .0 at any point in the study.
Abbreviations: FLS, flu-like symptoms; FLS-S, flu-like symptoms score; TSQM, Treatment Satisfaction Questionnaire for Medication.

week 4 (P,0.05). At all other time points, mean global satisfaction scores were numerically higher than baseline but
the difference was not statistically significant. Differences
in TSQM global satisfaction between the two cohorts, with
and without FLS, were statistically significant at weeks 12,
24, and 36 (P,0.05; Figure 2).
Changes in effectiveness score (not shown) indicated
a general improvement for patients both with and without
FLS, but none of the changes were significantly different
from baseline at any time point.

TSQM scores: by ISR status
ISRs were experienced by 64.4% (125/194) of patients at any
point in the study. TSQM scores were analyzed in patients
who did versus those who did not experience ISRs to determine the impact of ISRs on treatment satisfaction.
Statistically significant improvements in mean TSQM side
effect scores were observed from baseline to all visits except
week 24 for patients who experienced ISRs at any time point in
the study (Figure 3). For patients who did not experience ISRs
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(69/194), numerical improvements in TSQM side effect scores
were observed at weeks 4, 12, 24, and 36, and a numerical
reduction was observed at week 48, but no significant changes
from baseline values were observed at any time point.
Regardless of whether patients experienced ISRs, mean
TSQM convenience scores were significantly improved from
baseline to all subsequent visits (all P,0.0001). Similarly,
whether or not patients experienced ISRs, mean TSQM
global satisfaction scores were improved from baseline for
all time points except at week 48.
No significant changes in mean TSQM effectiveness
scores from baseline to any subsequent visit for patients
with or without ISRs were seen at any point in the study
(data not shown).

TSQM scores: by prior IFN
At screening, 97 patients were receiving IM IFN beta-1a
and 89 were receiving SC IFN beta-1a or beta-1b. TSQM
scores were analyzed by these two prior IFN therapy groups
to determine whether prior treatment had any impact on
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Dovepress

Improved satisfaction among MS patients on peginterferon beta-1a therapy

6LGHHIIHFWV



&RQYHQLHQFH

*OREDOVDWLVIDFWLRQ


3 

&KDQJHIURPEDVHOLQH

Patient Preference and Adherence downloaded from https://www.dovepress.com/ by 128.252.174.220 on 23-Oct-2018
For personal use only.



3 




±
±
±































:HHNVDIWHUEDVHOLQH
:LWK,65V Q 

:LWKRXW,65V Q 

Figure 3 Improvement in TSQM scores (with or without ISRs).
Notes: *P,0.05, **P,0.01, ***P,0.001, ****P,0.0001 compared with baseline. Data are mean values ±95% CI.
Abbreviations: ISR, injection-site reaction; TSQM, Treatment Satisfaction Questionnaire for Medication.

changes in treatment satisfaction associated with the switch
to peginterferon beta-1a.
After switching to peginterferon beta-1a, patients reported
stable or improved mean TSQM side effect scores from baseline to each visit (Figure 4). Mean TSQM side effect scores
improved significantly more for patients transitioning from
SC IFN beta-1a or beta-1b than for those transitioning from
IM IFN beta-1a at weeks 24 and 36 (P,0.01). In general, for
nonpegylated IFN therapies, the largest differences from baseline were seen at the earlier time points, and values returned
to baseline or near-baseline by the end of the study.
Mean TSQM convenience scores also significantly
improved from baseline to each visit for both nonpegylated IFN groups (all P,0.0001). The improvement was
significantly larger at every visit for the SC IFN beta-1a or
beta-1b treatment group compared with the IM IFN beta-1a
treatment group.
Significant improvements in mean TSQM global satisfaction scores from baseline were recorded in patients switching
from SC IFN beta-1a or beta-1b to peginterferon beta-1a at all
time points, while those previously on IM IFN beta-1a only

Patient Preference and Adherence 2018:12

showed significantly improved global satisfaction at weeks
12, 36, and 48 (Figure 4). Improvements in global satisfaction were significantly greater for the prior SC IFN beta-1a
or beta-1b group compared with the IM IFN beta-1a group
at weeks 4 and 24, with a trend toward greater improvement
at other time points.
Irrespective of prior IFN treatment, TSQM effectiveness scores were generally stable from baseline to each visit
after the switch to peginterferon beta-1a (data not shown).
Mean values showed a trend in improvement from baseline
for patients in the SC IFN beta-1a or beta-1b group, but no
changes were significantly different from baseline.

Discussion
The switch from nonpegylated IFNs to SC peginterferon
beta-1a every 2 weeks led to significant improvements
in patient satisfaction with side effects, convenience, and
global satisfaction scores on the TSQM as early as 4 weeks
after switching (the earliest time point assessed). Although
effectiveness scores were numerically higher (better), no
significant changes from baseline were seen, which was
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Figure 4 Improvement in TSQM scores (prior IFN treatment).
Notes: *P,0.05, **P,0.01, ***P,0.001, ****P,0.0001 compared with baseline. Data are mean values ±95% CI.
Abbreviations: IFN, interferon; IM, intramuscular; SC, subcutaneous; TSQM, Treatment Satisfaction Questionnaire for Medication.

expected given that the study did not select for patients who
were switching due to lack of efficacy.
As FLS are one of the most common AEs associated with
IFN therapies, we wanted to determine whether FLS influence treatment satisfaction after a switch to peginterferon
beta-1a. Therefore, the data were analyzed by stratifying
patients into those with or without FLS during the study.
Patients reported improvements from baseline in side effects,
convenience, and global satisfaction scores regardless of
experiencing FLS. Interestingly, although patients without
FLS showed significantly greater improvements in global
satisfaction than those with FLS, no significant differences
in side effect TSQM scores between the with-FLS and
without-FLS treatment groups were seen, suggesting that
the improvement in global satisfaction was most likely due
to the improvement in convenience scores.
Notably, patients who experienced ISRs showed increased
side effect satisfaction scores early after switching to peginterferon beta-1a. One explanation for this seemingly counterintuitive finding may be that these patients may have been
experiencing ISRs more frequently with their previous more
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frequently dosed IFN therapy when compared with every2-weeks dose administration with peginterferon beta-1a. This
observation is consistent with the overall ALLOW study,
in which the majority of FLS and ISR events were mild to
moderate, with only 2.5% and 6% of patients, respectively,
discontinuing due to these AEs.6
The switch from SC IFN beta-1a or beta-1b to SC
peginterferon beta-1a was associated with significantly greater
improvements in convenience and global satisfaction than the
switch from IM IFN beta-1a. Furthermore, satisfaction with
side effects was significantly improved following the treatment switch for patients on prior SC IFN beta-1a or beta-1b,
but only significant at one time point for patients on prior IM
IFN beta-1a (week 4). This finding may relate back to the
baseline incidence of ISRs, which tend to be more common
with SC IFN beta-1a or beta-1b than with IM IFN beta-1a;16
patients on prior SC IFN beta therapies are therefore likely to
show greater improvement in satisfaction with side effects.
Taken together, these results suggest that SC IFN beta-1a or
beta-1b patients are likely to gain the greatest benefit in treatment satisfaction by switching to peginterferon beta-1a.

Patient Preference and Adherence 2018:12
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This greater treatment satisfaction with peginterferon
beta-1a is likely driven largely by differences in dosing
schedule between the IFN therapies. In a 2-week period,
patients on SC IFN beta-1a or beta-1b inject six or seven
times, respectively; those on IM IFN beta-1a inject twice; and
those on SC peginterferon beta-1a inject once. It is perhaps
not surprising that patients on prior SC IFN beta exhibited
greater improvements in treatment satisfaction with peginterferon beta-1a. The reduction in injection frequency likely
led to reduced ISR frequency in those who had experienced
ISRs on SC IFN. Different routes of administration may also
have played a part in differences in convenience scores due
to lack of familiarity with SC injections in those who had
been treated with IM IFN beta-1a.
Although the TSQM has previously been utilized as a
patient-centered end point in RMS, this study is the first
to demonstrate that peginterferon beta-1a improves global
satisfaction, specifically side effect and convenience scores,
in patients with RMS previously treated with nonpegylated
IFN therapies. Previous studies have utilized the TSQM to
demonstrate improvements in treatment satisfaction over
time with other DMTs.17,18 One of these studies found a clinically meaningful relationship between each TSQM domain
and clinical outcomes such as treatment failure, relapse, and
AEs leading to discontinuation.17 In another study comparing
treatment satisfaction in patients switching from a nonpegylated IFN to fingolimod with those remaining on IFN,
significant improvement in all domains of satisfaction was
identified.18 Two cross-sectional studies demonstrated differences in TSQM scores between DMTs and, in agreement
with this study, found differences primarily in side effect and
convenience scores.19,20
The implications of improved treatment satisfaction
are likely to be substantial, potentially leading to increased
treatment adherence and, therefore, success.13 For example,
AEs and perceived lack of effectiveness have been shown to
impact long-term persistence with treatment.21,22 In addition,
improvements in convenience scores on the TSQM have been
associated with improved adherence.20 Since longer treatment
duration has been linked with improved long-term outcomes
in patients with RMS,23 components of treatment satisfaction
that have an impact on persistence and adherence are likely
to lead to improved treatment success.

Limitations
Limitations of this study include the fact that it was not
powered to evaluate differences in subgroups, though it did
include this as a secondary end point that provides important
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insights into what is important to patients, and the fact that
clinically significant improvement has not been well defined,
though previous studies have shown relationships between
clinical outcomes and TSQM domains.17

Conclusions
In summary, patients with RMS who switched from nonpegylated IFN beta therapies to SC peginterferon beta-1a
reported significant improvements in satisfaction with
treatment convenience, side effects, and global satisfaction as early as 4 weeks and continued improvements over
48 weeks. Regardless of FLS or ISR status, treatment with
peginterferon beta-1a significantly improved patient-reported
satisfaction with the convenience of treatment. Although
peginterferon beta-1a improved treatment satisfaction
regardless of prior IFN, the greatest improvements in global
satisfaction and convenience were seen in patients switching
from SC IFN beta-1a or beta-1b. Due to the administration
schedule, patients who require a switch may show high levels
of satisfaction and also find SC peginterferon beta-1a much
more convenient than previous IFNs. Patient perspective on
treatment satisfaction is very important to follow in clinical
practice when considering IFN therapy.
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Table S1 List of local ethics committees
Name

Location

Copernicus Group Independent Review Board
Western IRB
St Elizabeth’s Medical Center IRB
Washington University Human Research Protection Office
Lahey Hospital & Medical Center IRB
The University of Kansas Medical Center IRB
Christiana Care Institutional Review Board
University of Massachusetts Medical School IRB
Oklahoma Medical Research Foundation IRB
Henry Ford Health System’s IRB
Providence Health & Services IRB

Durham, NC, USA
Puyallup, WA, USA
Boston, MA, USA
St Louis, MO, USA
Burlington, MA, USA
Kansas City, KS, USA
Newark, DE, USA
Worcester, MA, USA
Oklahoma City, OK, USA
Detroit, MI, USA
Portland, OR, USA

Abbreviation: IRB, institutional review board.

Table S2 Baseline characteristics of patients enrolled in the ALLOW study
Characteristics

ITT population
(N=201)

Age, years
Mean (SD)
Median (range)
Female, n (%)
Time since MS symptom onset, years
Mean (SD)
Median (range)
Time since most recent relapse, mean (SD), years
Number of relapses within the last year
Mean (SD)
Median (range)

49.8 (9.9)
51 (18–65)
163 (81.1)
13.4 (8.5)
12 (1–52)
5.4 (4.62)
0.2 (0.63)
0 (0–4)

Abbreviations: ITT, intent-to-treat; MS, multiple sclerosis.
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